Table 1 Baseline Characteristics
Patient Characteristics | Total (N = 157) |
|---|---|
Age, median (range), y | 66 (27–87) |
Race, No. (%) | |
 White | 142 (90.5) |
 Black or African American | 7 (4.5) |
 Asian | 3 (1.9) |
 Native Hawaiian/Pacific Islander | 1 (0.6) |
 Other | 4 (2.5) |
Diagnosis, No. (%) | |
 Adenocarcinoma | 108 (68.8) |
 Squamous | 45 (28.7) |
 Other | 4 (2.5) |
Sex, No. (%) | |
 Female | 74 (47.1) |
 Male | 83 (52.9) |
Prior chemotherapy lines, No. (%) | |
 0 | 29 (18.5) |
 1 | 78 (49.7) |
 2 | 34 (21.7) |
 ≥3 | 16 (10.2) |
ECOG performance status, No. (%) | |
 0 | 40 (25.5) |
 1 | 75 (47.8) |
 2 | 37 (23.5) |
 3 | 5 (3.2) |
CNS disease, No. (%) | |
 Yes | 54 (34.4) |
 No | 103 (65.6) |
Immunotherapy drug, No. (%) | |
 Nivolumab | 146 (93.0) |
 Pembrolizumab | 11 (7.0) |
Immune adverse effects, No. (%) | |
 No | 98 (62.4) |
 Yes | 59 (37.6) |